Cambridge Quarterly of Healthcare Ethics 5 (2):300 (1996)
AbstractAn urgent need for standards and guidelines on genetic testing has arisen because of swift advances in research, facilitated by the Human Genome Project. The goals of the Human Genome Project include the identification of all genes and sequencing of the human genome. The project is currently ahead of schedule and under budget. We can expect an avalanche of genetic information, much of which will be relevant to human disease. In addition to the Human Genome Project, investigator-initiated research projects and commercial biotechnology laboratories are discovering human disease genes at a breathtaking pace. Technology transfer has been rapid and has led to the availability of numerous clinical tests within only a few years since the first disease gene yielded to the technique of positional cloning. Disease genes are selected for study for a number of reasons. Genes for rare diseases may be studied before more common disorders because they elucidate an important area of pathogenesis. Unfortunately, technology transfer to the clinic for rare tests is hindered by several factors. Standards need to be established to assure that genetic tests for rare diseases are not ignored or mismanaged in the rush to commercialize tests for more common human genetic diseases
Added to PP
Historical graph of downloads
References found in this work
No references found.
Citations of this work
No citations found.
Similar books and articles
The Concept of a Proposition in Classical and Quantum Physics.Robin Giles - 1979 - Studia Logica 38 (4):337 - 353.
The Widow, the Orphan, and the Stranger.Michael R. Paradiso-Michau - 2008 - Radical Philosophy Review 11 (2):187-195.
Ethical Issues in Funding Orphan Drug Research and Development.C. A. Gericke - 2005 - Journal of Medical Ethics 31 (3):164-168.
Extraordinary Pricing of Orphan Drugs: Is It a Socially Responsible Strategy for the U.S. Pharmaceutical Industry? [REVIEW]Thomas A. Hemphill - 2010 - Journal of Business Ethics 94 (2):225 - 242.
Do Linguistic Group Tests of Intelligence, Non-Linguistic Group Tests of Intelligence and Scholastic Tests Measure the Same Thing?J. G. Cannon - 1927 - Australasian Journal of Philosophy 5 (3):216 – 226.
Pharmacogenetic Interventions, Orphan Drugs, and Distributive Justice: The Role of Cost-Benefit Analysis.Arti K. Rai - 2002 - Social Philosophy and Policy 19 (2):246-270.
Are Genetic Self-Tests Dangerous? Assessing the Commercialization of Genetic Testing in Terms of Personal Autonomy.Ludvig Beckman - 2004 - Theoretical Medicine and Bioethics 25 (5-6):387-398.
Precursors to Theories of Mind in Nonhuman Brains.Stephen F. Walker - 1998 - Behavioral and Brain Sciences 21 (1):131-132.
2008 Revision of the Chinese Code of Ethical Use of Psychological Tests and Its Implementation Status.Yiqun Gan, Ran Meng, Haiping Chen & Hongsheng Che - 2012 - Ethics and Behavior 22 (1):30 - 41.
Strategic Corporate Social Responsibility and Orphan Drug Development: Insights From the US and the EU Biopharmaceutical Industry. [REVIEW]Olga Bruyaka, Hanko K. Zeitzmann, Isabelle Chalamon, Richard E. Wokutch & Pooja Thakur - 2013 - Journal of Business Ethics 117 (1):45-65.